ABSTRACT
From April 2023 to May 2024, an unusual epidemic of parvovirus B19 (B19V) infections occurred in France. The number of B19V IgM-positive serologies was four times higher than in the previous epidemic in 2019. Clinical data from emergency networks corroborated this observation. Morbidity and mortality consequences were observed in children through all data sources. In adults, the increase was only observed in laboratory-confirmed data. Physicians and decisionmakers should be informed in order to better prevent, diagnose and manage at-risk patients.
Subject(s)
Disease Outbreaks , Immunoglobulin M , Parvoviridae Infections , Parvovirus B19, Human , Humans , France/epidemiology , Parvovirus B19, Human/isolation & purification , Adult , Female , Male , Child , Parvoviridae Infections/epidemiology , Parvoviridae Infections/diagnosis , Immunoglobulin M/blood , Adolescent , Child, Preschool , Middle Aged , Antibodies, Viral/blood , Erythema Infectiosum/epidemiology , Erythema Infectiosum/diagnosis , Young Adult , Infant , AgedABSTRACT
A cluster of three confirmed autochthonous dengue cases was detected in October 2023 in the Val-de-Marne department neighbouring Paris, France. This marks the northernmost transmission of dengue in Europe reported to date. The epidemiological and microbiological investigations and the vector control measures are described. This event confirms the need for early case detection and response to contain dengue in Europe, especially given the 2024 Summer Olympic and Paralympic Games, when millions of visitors will visit the Greater Paris area.